Cargando…

Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma

SIMPLE SUMMARY: Multiple myeloma is the second most common hematological malignancy and while patients can have long responses to therapy, most patients will eventually develop treatment-resistant disease. Over the last thirty years, improved understanding of multiple myeloma and therapeutic advance...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ackley, James, Ochoa, Miguel Armenta, Ghoshal, Delta, Roy, Krishnendu, Lonial, Sagar, Boise, Lawrence H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507631/ https://www.ncbi.nlm.nih.gov/pubmed/34638271 http://dx.doi.org/10.3390/cancers13194787

Ejemplares similares

MAX is an epigenetic sensor of 5-carboxylcytosine and is altered in multiple myeloma
por: Wang, Dongxue, et al.
Publicado: (2017)

BCL2 Family Inhibitors in the Biology and Treatment of Multiple Myeloma
por: Gupta, Vikas A, et al.
Publicado: (2021)

Dexamethasone treatment promotes Bcl-2-dependence in multiple myeloma resulting in sensitivity to Venetoclax
por: Matulis, Shannon M., et al.
Publicado: (2015)

Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation
por: Shah, Shardule P., et al.
Publicado: (2016)

BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth
por: Deng, Jiusheng, et al.
Publicado: (2016)

Oncolytic Virotherapy for Multiple Myeloma: Past, Present, and Future
por: Thirukkumaran, Chandini M., et al.
Publicado: (2011)

Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma
por: Gu, Yanyan, et al.
Publicado: (2020)

Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives
por: Lonial, S, et al.
Publicado: (2016)

β adrenergic signaling regulates hematopoietic stem and progenitor cell commitment and therapy sensitivity in multiple myeloma
por: Nair, Remya, et al.
Publicado: (2022)

Past, Present, and a Glance into the Future of Multiple Myeloma Treatment
por: Elbezanti, Weam Othman, et al.
Publicado: (2023)

Minimal Residual Disease in Multiple Myeloma: Past, Present, and Future
por: Medina-Herrera, Alejandro, et al.
Publicado: (2023)

Smoldering multiple myeloma current treatment algorithms
por: Rajkumar, S. Vincent, et al.
Publicado: (2022)

The next generation of immunotherapy: keeping lung cancer in check
por: Somasundaram, Ashwin, et al.
Publicado: (2017)

Multiple myeloma immunoglobulin lambda translocations portend poor prognosis
por: Barwick, Benjamin G., et al.
Publicado: (2019)

Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib
por: Nooka, Ajay, et al.
Publicado: (2013)

Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax
por: Bajpai, R, et al.
Publicado: (2015)

Integrated Analysis of Whole-Genome Paired-End and Mate-Pair Sequencing Data for Identifying Genomic Structural Variations in Multiple Myeloma
por: Yang, Rendong, et al.
Publicado: (2014)

Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression
por: Gupta, Vikas A., et al.
Publicado: (2021)

Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future
por: Abramson, Hanley N.
Publicado: (2023)

Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma
por: Barwick, Benjamin G., et al.
Publicado: (2019)

Acquisition of a Multidrug Resistant Phenotype with a Proteasome Inhibitor in Multiple Myeloma
por: Gutman, Delia, et al.
Publicado: (2009)

Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma: Past, Present, and Future
por: Ozaki, Shuji, et al.
Publicado: (2014)

Therapeutic implications of mitochondrial stress–induced proteasome inhibitor resistance in multiple myeloma
por: Sharma, Aditi, et al.
Publicado: (2022)

Immunotherapy for Multiple Myeloma
por: Kröger, Nicolaus, et al.
Publicado: (2012)

Immunotherapy for Multiple Myeloma
por: Tamura, Hideto, et al.
Publicado: (2019)

Immunotherapy in Multiple Myeloma
por: Soekojo, Cinnie Yentia, et al.
Publicado: (2020)

Game of Bones: How Myeloma Manipulates Its Microenvironment
por: Moser-Katz, Tyler, et al.
Publicado: (2021)

Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma
por: Bajpai, Richa, et al.
Publicado: (2020)

Novel Immunotherapies and Combinations: The Future Landscape of Multiple Myeloma Treatment
por: Morè, Sonia, et al.
Publicado: (2023)

Is immunotherapy here to stay in multiple myeloma?
por: Rodríguez-Otero, Paula, et al.
Publicado: (2017)

Association of response endpoints with survival outcomes in multiple myeloma
por: Lonial, S, et al.
Publicado: (2014)

Ascorbic Acid Augments Arsenic-Mediated Cell Death in Multiple Myeloma (MM) Cells
por: Grad, Jennifer M., et al.
Publicado: (2001)

Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone
por: Schmidt, Timothy M., et al.
Publicado: (2019)

Induction therapy and stem-cell mobilization in myeloma, look at the past to plan the future()
por: Schaffel, Rony
Publicado: (2019)

BCC or not: Sufu keeps it in check
por: Yin, Wen-Chi, et al.
Publicado: (2015)

Keeping carbon dioxide in check
por: Garcia, Alfredo J, et al.
Publicado: (2017)

The Role of Immunotherapy in Multiple Myeloma
por: Kocoglu, Mehmet, et al.
Publicado: (2016)

Editorial: Immunotherapy in Multiple Myeloma
por: Giuliani, Nicola, et al.
Publicado: (2019)

Introduction to “Immunotherapies for Multiple Myeloma”
por: Offidani, Massimo, et al.
Publicado: (2020)

Cellular immunotherapy in multiple myeloma
por: Vo, Manh-Cuong, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_bui2bdvc8v5tstj490s9sncr2j